How would you treat a patient with metastatic urothelial carcinoma with early progression on maintenance immunotherapy?

If the patient received <2 months of immunotherapy, would you continue immunotherapy alone or transition to enfortumab monotherapy or EV+Pembro?

Answer from: Medical Oncologist at Academic Institution

It would depend on the clinical scenario, specifically the disease volume, degree of progression, and whether the patient is deriving clinical benefit despite radiographic progression. Significant early progression in a patient with high disease volume/symptoms is a poor prognostic indicator and we ...

Comments

Medical Oncologist at Presbyterian Healthcare Services
Would you re-treat with platinum-based chemotherap...

Answer from: Medical Oncologist at Community Practice

Would continue and monitor by the measurable disease.

Please select the option that best describes you:

How would you treat a patient with metastatic urothelial carcinoma with early progression on maintenance immunotherapy?

Related Questions